FR in Stored Plasma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2008 by Royal Marsden NHS Foundation Trust.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Institute of Cancer Research, United Kingdom
Information provided by:
Royal Marsden NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT00787514
First received: November 6, 2008
Last updated: NA
Last verified: November 2008
History: No changes posted
  Purpose

The folate receptor (FR) is a cell over expressed on the surface of certain cancers, this occurs most frequently in ovarian cancers. Some normal tissues also express the FR, however in these normal tissues, the FR is usually located on the tissue surface that is inaccessible to circulating drugs. As such, drugs which target the FR may potentially be used to target cancers which overexpress the FR while reducing toxicity to normal tissues. Therefore the ability to measure FR levels from different cancer types may help to select patients who are most likely to benefit from treatment with FR targeted therapies. Once such drug BGC945 is currently being tested in preclinical study at the Institute of Cancer Research


Condition
Ovarian Cancer

Study Type: Observational
Official Title: Measurement of the Folate Receptor in Stored Plasma From Patients With Ovarian Cancer

Resource links provided by NLM:


Further study details as provided by Royal Marsden NHS Foundation Trust:

Primary Outcome Measures:
  • To measure the levels of soluble folate receptor in stored plasma obtained from patients with ovarian cancer [ Designated as safety issue: No ]

Estimated Enrollment: 27
Study Start Date: July 2008
Estimated Study Completion Date: February 2011
Estimated Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Detailed Description:

FR may be released from the cancer cells in the blood. We have developed a method in the laboratory which has been able to measure the FR obtained from cancer cells in culture which has been added into blood. We would like to study if this method is able to measure the FR in stored plasma samples obtained from patients with ovarian cancer, so that it may be developed as a method for selecting patients for FR-target treatments such as BGC 945.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

In the first stage of the study 13 samples will be analysed. If thee is one or more positive results the study will progress to the 2nd state to include 14 more samples.

Criteria

Inclusion Criteria:

  • Patients with ovarian cancer who have given informed consent to have blood collected for the plasma bank in the 'Pharmacogenetics and proteomics studies in patients receiving novel anticaner agents' study.

Exclusion Criteria:

  • Patients who have withdrawn consent form their blood stored within the 'Pharmacogenetics and proteomics studies in patients receiving novel anticancer agents' study to be used for research.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00787514

Contacts
Contact: Stan Kaye 02086613539 stan.kaye@rmh.nhs.uk
Contact: Matthew Ng 02087224283 matthew.ng@icr.ac.uk

Locations
United Kingdom
Royal Marsden NHS Foundation Trust Recruiting
Sutton, Surrey, United Kingdom, SM2 5PT
Contact: Stan Kaye    02086613541    stan.kaye@rmh.nhs.uk   
Contact: Matthew Ng    02087224283    matthew.ng@rmh.nhs.uk   
Principal Investigator: Stan Kaye         
Sponsors and Collaborators
Royal Marsden NHS Foundation Trust
Institute of Cancer Research, United Kingdom
  More Information

No publications provided

Responsible Party: Prof Stan Kaye, Institute of Cancer Research
ClinicalTrials.gov Identifier: NCT00787514     History of Changes
Other Study ID Numbers: CCR3029
Study First Received: November 6, 2008
Last Updated: November 6, 2008
Health Authority: United Kingdom: National Health Service

Keywords provided by Royal Marsden NHS Foundation Trust:
ovarian cancer, folate receptor, plasma

Additional relevant MeSH terms:
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders

ClinicalTrials.gov processed this record on September 18, 2014